Dr. Reddy's Laboratories Limited
NSE: DRREDDY | Information Technology
Market Fundamentals
Stock Intelligence & News
Dr Reddy's Terminates Novartis India Agreement After Ownership Change
Under the agreement, Dr Reddy's had been granted the exclusive and non-transferable right to promote, distribute and sell certain products specified in the agreement.
Read Full Analysis →Dr Reddys Laboratories Ltd (500124)
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Press Release
Read Full Analysis →US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipeline
Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw significant drops in their net profits and operating margins. However, their domestic businesses continued to perform well, offering a positive outlook. Obesity therapies and specialty product launches are expected to drive future growth for these companies. Analysts have consequently reduced earnings forecasts for the upcoming fiscal years.
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Dr Reddy's Shares Fall Nearly 7% After Weaker-Than-Expected Q1 Results
Dr Reddy's shares fell upto 6.92%, later recovering slightly to dip by 2.82% at Rs 1,149.50 apiece.
Read Full Analysis →Dr Reddy's Q1 Review: Brokerages Cut Targets After Q1 Miss; Weak US Business, Semaglutide Hit Key Triggers
Morgan Stanley, BofA and Citi cut target prices on Dr Reddy's after a weak Q1. Here's what they said about semaglutide, margins and H2 recovery.
Read Full Analysis →Stocks in news: Infosys, IndusInd Bank, Eternal, Adani Green, Dr Reddy's
Indian markets experienced a decline on Wednesday due to global and geopolitical concerns. IndusInd Bank reported a significant profit increase while Eternal saw substantial net profit growth. BPCL, however, posted a considerable loss in the first quarter. Adani Green announced a moderate profit rise, and Dr Reddy's profit declined. Several other companies like Infosys will announce their first quarter results today.
Read Full Analysis →Get instant alerts when DRREDDY breaks news
Join investors who track Dr. Reddy's Laboratories Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for DRREDDY?
DRREDDY is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for Dr. Reddy's Laboratories Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding DRREDDY to your custom watchlist.